Tadalafil Tablet
Product Images NDC 71335-2363

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71335-2363). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

This text mentions different types of blood pressure readings: standing diastolic BP, supine diastolic BP, standing systolic BP, and supine systolic BP. It also indicates a time marker in hours for each type of blood pressure measurement.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

The text describes a graph showing the effect of Tadalafil 20 mg and doxazosin 8 mg on standing systolic blood pressure (BP) in millimeters of mercury (mmHg).*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

This text provides information about the systolic blood pressure measured at different time points after the administration of different drugs. The study includes the use of 20 mg of tadalafil and 8 mg of doxazosin at 08:00 and 20:00, as well as a placebo with doxazosin. The data can be used to evaluate the effects of these medications on blood pressure over time.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

This text indicates the evaluation of the change in IPSS Total Score in a study using Tadalafil tablets 5 mg compared to a placebo over a duration of 12 weeks. The asterisk (*) indicates statistical significance (p<0.001).*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

LS Mean Change from Baseline for TadalafilFinasteride compared to PlaceboFinasteride. The text also mentions Least Squares Treatment Difference.*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

This text seems to show a comparison between Tadalafil tablets at 5 mg dosage and a placebo. The graph displays a significant difference with a p-value of less than 0.01. The graph also illustrates the duration of treatment in weeks along the x-axis.*

FDA Label Image

Label (Lbl713352363)

This text provides information on Tadalafil Tablets, USP containing 2.5 mg of Tadalafil per film-coated tablet. The tablets should not be split, and the entire dose should be taken. It is advised to keep the tablets out of reach of children and store them at 25°C with excursions permitted between 15° to 30°C. The tablets are to be dispensed in a tight container and were repackaged by Bryant Ranch Prepack, Inc. Manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.